# Medical Cannabis in Palliative Care for Infectious Diseases > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/d71-medical-cannabis-in-palliative-care-for-infectious-diseases-png/ > **Published:** 2026-09-04T23:01:14-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:47:07-04:00 > **Clinical Summary:** Pain, nausea, appetite loss, anxiety, and depression in palliative care for infectious disease, and where medical cannabis helps and why it is underused. --- [← Back to Palliative Care Summary Hub](https://cedclinic.com/topic-palliative-care/) Table of Contents - [πŸ” CED Perspective Lens: Medical Cannabis in Palliative Care for Infectious Diseases](#_CED_Perspective_Lens_Medical_Cannabis_in_Palliative_Care_for_Infectious_Diseases) - [Medical Cannabis in Palliative Care for Infectious Diseases](#Medical_Cannabis_in_Palliative_Care_for_Infectious_Diseases) - [Extensive Review of Applications](#Extensive_Review_of_Applications)[Pain Control](#Pain_Control) - [Nausea and Appetite Loss](#Nausea_and_Appetite_Loss) - [Anxiety and Depression](#Anxiety_and_Depression) - [Lack of Awareness](#Lack_of_Awareness) - [Comparison Table](#Comparison_Table) - [Precautionary Note](#Precautionary_Note) - [References](#References)[🌐 Explore Related CED Clinical Summary Hubs & Research](#_Explore_Related_CED_Clinical_Summary_Hubs_Research) #### πŸ” CED Perspective Lens: Medical Cannabis in Palliative Care for Infectious Diseases Dr. Benjamin Caplan, MD **🌱 Clinical Focus:** Detailed evidence review on medical cannabis in palliative care for infectious diseases, physiology, and therapeutic applications. **πŸ’‘ Clinical Guidance:** Dosing considerations, bioavailability pathways, and evidence-grounded risk management. **πŸ“– Research & Data:** Preserving authoritative charts, diagrams, clinical tables, and scientific reference data. ## Medical Cannabis in Palliative Care for Infectious Diseases ## Extensive Review of Applications Medical cannabis has a burgeoning role in palliative care, particularly in managing symptoms such as pain, nausea, appetite loss, [anxiety](https://cedclinic.com/topic-anxiety-depression/), and depression. Despite its potential benefits, medical cannabis remains underutilized and poorly understood in the context of palliative care. ### Pain Control Cannabis, particularly CBD and THC, has shown promise in [pain management](https://cedclinic.com/cbd-gummies-pain-management/). Both compounds interact with the endocannabinoid system, reducing inflammation and modulating pain signals[1](http://Russo, E. B. (2016). Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management, 4, 245-259). ### Nausea and Appetite Loss Cannabinoids can be particularly effective in combating nausea and vomiting, often side effects of chemotherapy or antiretroviral therapies. THC stimulates the appetite by interacting with CB1 receptors in the brain[2](http://Parker, L. A., et al. (2015). Regulation of nausea and vomiting by cannabinoids. British Journal of Pharmacology, 163, 1411 to 1422). ### Anxiety and Depression CBD has shown promise as an anxiolytic and antidepressant by modulating serotonin levels[3](http://Blessing, E. M., et al. (2015). Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics, 12(4), 825-836.). ## Lack of Awareness In recent history, most clinicians in palliative care are unaware of the potential benefits of cannabis-based treatments. This results in a scenario where patients self-experiment, risking adverse effects at a vulnerable time. The expertise of medical providers like Dr. Caplan at CED Clinic can guide patients to safer, more effective symptom management. ## Comparison Table Symptom Mechanism of Action Best Suited Formulations Duration in Body Pain Anti-inflammatory, analgesic Oral, Inhalation, Topical 2-6 hours Nausea Anti-emetic Oral, Sublingual 4-8 hours Appetite Loss Stimulation of CB1 receptors Oral, Inhalation 2-6 hours Anxiety Serotonin modulation Sublingual, Oral 4-8 hours Depression Serotonin modulation Sublingual, Oral 4-8 hours ## Precautionary Note Patients with the following conditions should consult Dr. Caplan at CED Clinic for more specialized, evidence-based guidance: - Cardiovascular diseases - Liver disorders - Pregnancy and breastfeeding - History of substance abuse ## References - Russo, E. B. (2016). Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management, 4, 245-259. - Parker, L. A., et al. (2015). Regulation of nausea and vomiting by cannabinoids. British Journal of Pharmacology, 163, 1411 to 1422. - Blessing, E. M., et al. (2015). Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics, 12(4), 825-836. πŸ“— Note: This diagram’s your first chord; the book’s your rock anthem. [Strum along by clicking here πŸ“—](https://amzn.to/4a35lhE) [https://amzn.to/4a35lhE](https://amzn.to/4a35lhE)[Unlock the world of medical cannabis with The Doctor-Approved Cannabis Handbook.](https://amzn.to/4a35lhE) [← Back to Palliative Care Summary Hub](https://cedclinic.com/topic-palliative-care/) #### 🌐 Explore Related CED Clinical Summary Hubs & Research [😴 Sleep & Insomnia Hub β†’](https://cedclinic.com/topic-cannabis-sleep-insomnia/) [🧬 Bioavailability Hub β†’](https://cedclinic.com/topic-bioavailability-pathway-decisions/) [πŸ’Š Clinical Dosing Hub β†’](https://cedclinic.com/topic-dosage/) [⚑ Pain Control Hub β†’](https://cedclinic.com/topic-pain-control/) --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR Β§ 164.514(b)) and criteria for secondary research exemption under 45 CFR Β§ 46.104(d)(4).